2024
Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis
Lansky A, Grubman D, Dwyer M, Zivadinov R, Parise H, Moses J, Shah T, Pietras C, Tirziu D, Gambone L, Leon M, Nazif T, Messé S. Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis. Journal Of The American College Of Cardiology 2024, 84: 712-722. PMID: 39142725, DOI: 10.1016/j.jacc.2024.05.055.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementClinical ischemic strokeAcute brain infarctionDW-MRIReceiver operating characteristicIschemic strokeTranscatheter aortic valve replacement resultBrain infarctionPatient-level pooled analysisC-statisticBrain MRI lesionsAcute ischemic brain injuryDiffusion-weighted magnetic resonance imagingAortic valve replacementIndividual lesion volumesCore laboratory analysisIschemic brain injuryPredicting ischemic strokeMagnetic resonance imagingStroke Prevention TrialMRI lesionsValve replacementDW-MRI acquisitionsPatient-level dataPooled analysis
2023
Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Huang H, Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz C, Parise H, Lansky A. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open 2023, 13: e067910. PMID: 36828654, PMCID: PMC9971831, DOI: 10.1136/bmjopen-2022-067910.Peer-Reviewed Original ResearchConceptsStandard of careHigh-intensity rosuvastatinElectronic medical recordsCOVID-19 diseaseMedical recordsPrimary endpointThromboembolic eventsYale New Haven Health SystemSevere COVID-19 diseaseCOVID-19Prespecified primary endpointVenous thromboembolic eventsRisk of progressionCombination of colchicineSafety monitoring boardCare armHispanics/LatinosTherapeutic anticoagulationIndex hospitalisationIll patientsMedian ageFuture trialsEffect of colchicineClinical trialsMonitoring board
2022
Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation
Persu A, Maes F, Toennes S, Ritscher S, Georges C, Wallemacq P, Haratani N, Parise H, Fischell T, Lauder L, Mahfoud F. Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation. Blood Pressure 2022, 31: 109-117. PMID: 35575248, DOI: 10.1080/08037051.2022.2074367.Peer-Reviewed Original ResearchConceptsRenal denervationDrug adherenceBlood pressure changesNon-adherent patientsPoor drug adherenceTreatment-resistant hypertensionSham-controlled trialBlood pressure responseSystolic blood pressureUncontrolled hypertensionAntihypertensive medicationsResistant hypertensionSuch patientsBlood pressureAntihypertensive drugsDenervationMean 24Partial adherencePatientsFull adherenceUrinary detectionHypertensionPressure changesLiquid chromatography-tandem mass spectrometryAdherence
2016
Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2
Peguero J, Presti S, Issa O, Podesta C, Parise H, Layka A, Brenes J, Lamelas J, Lamas G. Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2. American Heart Journal 2016, 177: 153-159. PMID: 27297861, DOI: 10.1016/j.ahj.2016.04.019.Peer-Reviewed Original ResearchConceptsR2CHADS2 scoresOperative mortalityPermanent strokePostoperative eventsRenal failureCoronary artery bypass graft surgeryArtery bypass graft surgeryThoracic Surgeons scoreBypass graft surgeryCHA2DS2-VASc scorePostoperative renal failurePredictor of morbidityCongestive heart failureCardiac surgery outcomesEnd-point variablesCHA2DS2-VAScPrior strokeGraft surgeryPostoperative outcomesValve surgerySurgeons scoreHeart failureSurgery outcomesCardiovascular surgeryInclusion criteriaPolymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial
Costa R, Abizaid A, Mehran R, Schofer J, Schuler G, Hauptmann K, Magalhães M, Parise H, Grube E, Investigators B. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovascular Interventions 2016, 9: 51-64. PMID: 26762911, DOI: 10.1016/j.jcin.2015.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsFemaleGermanyHumansKaplan-Meier EstimateMaleMiddle AgedNeointimaPaclitaxelPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSingle-Blind MethodSirolimusStainless SteelSurface PropertiesTime FactorsTreatment OutcomeConceptsStent late lumen lossPaclitaxel-eluting stentsLate lumen lossDrug-coated stentsStent thrombosisBiolimus A9First-generation paclitaxel-eluting stentsDe novo coronary lesionsMajor adverse cardiac eventsPolymer-free biolimus A9Probable stent thrombosisAdverse cardiac eventsNovo coronary lesionsTarget lesion revascularizationClinical event ratesLong-term outcomesLesion revascularizationAngiographic followCardiac eventsClinical outcomesCoronary lesionsLesions 4Lumen lossStandard doseStainless steel platform
2014
Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Herrmann J, Gersh B, Goldfinger J, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Brener S, Parise H, Fahy M, McAndrew T, Stone G, Mehran R. Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2014, 114: 9-16. PMID: 24846807, DOI: 10.1016/j.amjcard.2014.03.057.Peer-Reviewed Original ResearchConceptsST-segment myocardial infarctionBody mass indexLong-term outcomesHigher body mass indexBMI quartilesMass indexMyocardial infarctionIschemia-driven target vessel revascularizationAcute Myocardial Infarction trialHigher-weight patientsLower cardiac mortalityLowest BMI quartileCardiovascular risk profileMajor bleeding eventsMyocardial Infarction trialTarget vessel revascularizationLong-term mortalityAcute cardiovascular eventsAcute myocardial infarctionLarge multinational cohortBleeding eventsHarmonizing OutcomesHospital mortalityMyocardial reinfarctionNoncardiac mortalityImpact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials
Kedhi E, Généreux P, Palmerini T, McAndrew T, Parise H, Mehran R, Dangas G, Stone G. Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials. Journal Of The American College Of Cardiology 2014, 63: 2111-2118. PMID: 24632279, DOI: 10.1016/j.jacc.2014.01.064.Peer-Reviewed Original ResearchConceptsDiabetes mellitusRepeat revascularizationMyocardial infarctionLesion complexityStent outcomesCardiac deathType A/B1 lesionsType B2/C lesionsB2/C lesionsPropensity score-matched groupsCoronary lesion complexityTarget vessel revascularizationPatient-level dataB1 lesionsNoncomplex lesionsVessel revascularizationDiabetic statusC lesionsDES eraRandomized trialsRisk factorsTarget lesionsDES safetyTreatment outcomesBaseline differences
2013
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy
Nazif T, Mehran R, Lee E, Fahy M, Parise H, Stone G, Kirtane A. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal 2013, 167: 43-50. PMID: 24332141, DOI: 10.1016/j.ahj.2013.10.013.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa receptor inhibitorsNet adverse clinical eventsMajor adverse cardiac eventsHigh-risk acute coronary syndromesAcute coronary syndromeMajor bleedingCoronary syndromeComposite major adverse cardiac eventsIIb/IIIa receptor inhibitorsGlycoprotein IIb/IIIa inhibitorsEarly invasive management strategyIIb/IIIa inhibitorsInvasive management strategySafety of tirofibanAdverse cardiac eventsSimilar clinical outcomesAdverse clinical eventsUse of tirofibanComparative effectiveness analysisSignificant differencesACUITY trialAcute CatheterizationUpstream tirofibanMultivariable adjustmentUpstream therapyRelationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial
Dizon J, Brener S, Maehara A, Witzenbichler B, Biviano A, Godlewski J, Parise H, Dambrink J, Mehran R, Gibson C, Stone G. Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 78-83. PMID: 24562806, PMCID: PMC3932776, DOI: 10.1177/2048872613508658.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAnterior Wall Myocardial InfarctionAntibodies, MonoclonalCoronary AngiographyElectrocardiographyFemaleHeart VentriclesHumansImmunoglobulin Fab FragmentsInfusions, IntravenousMagnetic Resonance Imaging, CineMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexTreatment OutcomeConceptsST-segment elevation myocardial infarctionST-segment resolutionST-segment elevationAnterior ST-segment elevation myocardial infarctionResidual ST-segment elevationDays post interventionINFUSE-AMI trialMin post interventionInfarct sizeMicrovascular obstructionPost interventionInfarct massBaseline ST-segment elevationPrimary percutaneous coronary interventionSimple ECG parametersUltimate infarct sizeElevation myocardial infarctionPercutaneous coronary interventionInfarct-related leadsTotal LV massQ wave changesSignificant Q wavesECG methodSingle leadBolus abciximabRelationship Between Myocardial Reperfusion, Infarct Size, and Mortality The INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) Trial
Brener S, Maehara A, Dizon J, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink J, Mehran R, Oldroyd K, Gibson C, Stone G. Relationship Between Myocardial Reperfusion, Infarct Size, and Mortality The INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2013, 6: 718-724. PMID: 23866184, DOI: 10.1016/j.jcin.2013.03.013.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAnterior Wall Myocardial InfarctionAntibodies, MonoclonalAnticoagulantsChi-Square DistributionCoronary AngiographyCoronary CirculationFemaleHumansImmunoglobulin Fab FragmentsMagnetic Resonance Imaging, CineMaleMicrocirculationMiddle AgedMyocardiumPercutaneous Coronary InterventionRecovery of FunctionRisk FactorsSuctionThrombectomyTime FactorsTreatment OutcomeConceptsINFUSE-AMI trialST-segment elevation myocardial infarctionElevation myocardial infarctionMBG 2/3Infarct sizeMicrocirculatory reperfusionMicrovascular obstructionEjection fractionMyocardial infarctionAnterior ST-segment elevation myocardial infarctionST-segment elevation myocardial infarction (STEMI) patientsElevation myocardial infarction patientsPrimary percutaneous coronary interventionManual thrombus aspirationPercutaneous coronary interventionSmaller infarct sizeMyocardial infarction patientsRate of deathBolus abciximabIntracoronary abciximabMBG 0/1Primary endpointCoronary interventionThrombus aspirationMyocardial reperfusionImpact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction
MINDRESCU C, BRENER S, GUERCHICOFF A, FAHY M, PARISE H, MEHRAN R, STONE G. Impact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction. Journal Of Interventional Cardiology 2013, 26: 319-324. PMID: 23795656, DOI: 10.1111/joic.12038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionTarget vessel revascularizationPercutaneous coronary interventionPrimary percutaneous coronary interventionElevation myocardial infarctionMyocardial infarctionCoronary interventionStent thrombosisAcute Myocardial Infarction trialMyocardial Infarction trialOutcomes of patientsRate of revascularizationAngiographic Follow-upSAF groupRate of deathHarmonizing OutcomesVessel revascularizationCerebral eventsMI ratesFollow-upPatientsRevascularizationInfarctionComposite rateDeathImpact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery
Wöhrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, Grines C, McAndrew T, Parise H, Sergie Z, Mehran R, Stone G. Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery. The American Journal Of Cardiology 2013, 112: 753-760. PMID: 23746479, DOI: 10.1016/j.amjcard.2013.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, PhytogenicAntithrombinsCoronary AngiographyCoronary VesselsDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansMaleMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPercutaneous Coronary InterventionProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionPaclitaxel-eluting stentingImpact of bivalirudinTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationCoronary interventionCardiac deathPrimary PCIGlycoprotein IIb/IIIa inhibitorsIschemia-driven target vessel revascularizationIIb/IIIa inhibitorsLeft anterior descending (LAD) arteryHORIZONS-AMI trialMajor bleeding eventsUse of bivalirudinAnterior descending (LAD) arteryElevation myocardial infarctionBare-metal stentingSignificant lower rateLower ratesBleeding eventsCardiovascular eventsRevascularization ratesInfarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial
Brener S, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink J, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson C, Stone G. Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. American Heart Journal 2013, 166: 64-70. PMID: 23816023, DOI: 10.1016/j.ahj.2013.03.029.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAntibodies, MonoclonalCardiac CatheterizationCoronary AngiographyCoronary StenosisCoronary VesselsElectrocardiographyFemaleHumansImmunoglobulin Fab FragmentsInjections, Intra-ArterialMagnetic Resonance Imaging, CineMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexSurvival RateThrombectomyTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionInfarct sizeMyocardial infarctionAnterior ST-segment elevation myocardial infarctionMyocardial blush grade 2/3Myocardial infarction flow 3Primary percutaneous coronary interventionINFUSE-AMI trialMyocardial Infarction trialPrimary end pointST-segment resolutionPercutaneous coronary interventionSeptal perforator branchExtent of myocardiumEffect of ICSBivalirudin anticoagulationBolus abciximabFinal ThrombolysisIntracoronary abciximabKillip classLAD infarctsReperfusion therapyArtery occlusionCoronary intervention
2012
Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Fiocca L, Guagliumi G, Rossini R, Parise H, Musumeci G, Sirbu V, Lortkipanidze N, Yu J, Mihalcsik L, Vassileva A, Valsecchi O, Gavazzi A, Mehran R, Stone G. Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. The American Journal Of Cardiology 2012, 111: 196-201. PMID: 23111141, DOI: 10.1016/j.amjcard.2012.09.019.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionAcute Myocardial Infarction trialKillip class IIIMyocardial Infarction trialOutcomes of patientsElevation myocardial infarctionHarmonizing OutcomesMyocardial infarctionMyocardial Infarction flow grade 3Major adverse cardiovascular eventsNet adverse clinical eventsClass IIIHORIZONS-AMI trialTrial eligible groupAdverse cardiovascular eventsHigh-risk featuresAdverse clinical eventsVentricular ejection fractionBroad inclusion criteriaFinal ThrombolysisMajor bleedingCardiovascular eventsCause mortalityAdverse eventsBaseline characteristicsStent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.
Kedhi E, Stone G, Kereiakes D, Serruys P, Parise H, Fahy M, Simonton C, Sudhir K, Sood P, Smits P. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention 2012, 8: 599-606. PMID: 22995087, DOI: 10.4244/eijv8i5a92.Peer-Reviewed Original ResearchConceptsDAPT discontinuationCardiac deathSPIRIT IIST ratesDual antiplatelet therapy discontinuationDual antiplatelet therapy interruptionSPIRIT IIIAntiplatelet therapy discontinuationAntiplatelet therapy interruptionLarge pooled analysisRandomised clinical trialsTwo-year ratePatient-level databaseLog-rank testPES cohortTherapy discontinuationTherapy interruptionRandomised trialsStent thrombosisPaclitaxel-eluting stent deploymentPooled analysisClinical trialsDiscontinuationStent deploymentComposite rateImpact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial
Stone G, Clayton T, Mehran R, Dangas G, Parise H, Fahy M, Pocock S. Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. American Heart Journal 2012, 163: 522-529. PMID: 22424026, DOI: 10.1016/j.ahj.2011.11.016.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionAcute coronary syndromeBlood cell transfusionMajor bleedingRBC transfusionCell transfusionCoronary syndromeCardiac surgerySubsequent mortalityUrgent Intervention Triage Strategy (ACUITY) trialAllogeneic blood product transfusionInternational prospective trialsCoronary artery bypassMajor hemorrhagic complicationsOne-year mortalityBlood product transfusionCovariate-adjusted Cox modelsPrior retrospective studiesFresh frozen plasmaAcute CatheterizationArtery bypassHemorrhagic complicationsProduct transfusionHospital dischargeProspective trial
2011
Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey T, Fahy M, Parise H, Stone G. Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 760-768. PMID: 21777884, DOI: 10.1016/j.jcin.2011.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyDiabetes MellitusDose-Response Relationship, DrugDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionPeptide FragmentsProspective StudiesRecombinant ProteinsStentsSurvival RateTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionHORIZONS-AMI trialDiabetes mellitusDiabetic patientsMyocardial infarctionPrimary PCIMajor adverse cardiac eventsIIb/IIIa inhibitorsEffectiveness of bivalirudinEfficacy of bivalirudinAdverse cardiac eventsAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionAcute myocardial infarctionMajor bleedingCardiac mortalityCoronary syndromeAnticoagulant therapyCardiac eventsCoronary interventionCardiac deathUnfractionated heparinHeparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarctionPredictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes D, Smits P, Kedhi E, Parise H, Fahy M, Serruys P, Stone G. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention 2011, 7: 74-83. PMID: 21550906, DOI: 10.4244/eijv7i1a14.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsPaclitaxel-eluting stentsMyocardial infarctionIndependent predictorsID-TLRID-TVRCardiac deathCardiovascular eventsSPIRIT IIStent deploymentDrug-eluting stent deploymentPredictors of deathAdverse clinical outcomesCoronary artery diseaseSuperior clinical efficacyIschaemia-driven revascularisationNumber of lesionsArtery diseaseCoronary stentingClinical outcomesClinical efficacyAdverse outcomesPaclitaxel-eluting stent deploymentClinical trialsMeta-Analysis of Randomized Studies Comparing Intravascular Ultrasound Versus Angiographic Guidance of Percutaneous Coronary Intervention in Pre–Drug-Eluting Stent Era
Parise H, Maehara A, Stone G, Leon M, Mintz G. Meta-Analysis of Randomized Studies Comparing Intravascular Ultrasound Versus Angiographic Guidance of Percutaneous Coronary Intervention in Pre–Drug-Eluting Stent Era. The American Journal Of Cardiology 2011, 107: 374-382. PMID: 21257001, DOI: 10.1016/j.amjcard.2010.09.030.Peer-Reviewed Original ResearchConceptsBare metal stent implantationMetal stent implantationMajor adverse cardiac eventsAdverse cardiac eventsPercutaneous coronary interventionIVUS guidanceStent implantationAngiographic restenosisCardiac eventsCoronary interventionMyocardial infarctionIntravascular ultrasoundOverall major adverse cardiac eventsSingle-center studyAcute procedural resultsMinimum lumen diameterRevascularization ratesStent eraBalloon angioplastyProcedural resultsStent studiesAngiographic guidanceNoninferiority trialMeta-AnalysisLumen diameter